- Home
- POAI vs ALZN Comparison
POAI vs ALZN Comparison
Compare POAI & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- ALZN
- Stock Information
- Founded
- POAI 2002
- ALZN 2016
- Country
- POAI United States
- ALZN United States
- Employees
- POAI N/A
- ALZN N/A
- Industry
- POAI Industrial Specialties
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- POAI Health Care
- ALZN Health Care
- Exchange
- POAI Nasdaq
- ALZN Nasdaq
- Market Cap
- POAI 7.8M
- ALZN 7.4M
- IPO Year
- POAI N/A
- ALZN 2021
- Fundamental
- Price
- POAI $0.93
- ALZN $2.35
- Analyst Decision
- POAI Hold
- ALZN Strong Buy
- Analyst Count
- POAI 1
- ALZN 1
- Target Price
- POAI N/A
- ALZN $45.00
- AVG Volume (30 Days)
- POAI 122.8K
- ALZN 64.9K
- Earning Date
- POAI 11-11-2025
- ALZN 09-10-2025
- Dividend Yield
- POAI N/A
- ALZN N/A
- EPS Growth
- POAI N/A
- ALZN N/A
- EPS
- POAI N/A
- ALZN N/A
- Revenue
- POAI $1,664,696.00
- ALZN N/A
- Revenue This Year
- POAI $486.27
- ALZN N/A
- Revenue Next Year
- POAI $65.50
- ALZN N/A
- P/E Ratio
- POAI N/A
- ALZN N/A
- Revenue Growth
- POAI 71.65
- ALZN N/A
- 52 Week Low
- POAI $0.55
- ALZN $2.06
- 52 Week High
- POAI $3.06
- ALZN $17.73
- Technical
- Relative Strength Index (RSI)
- POAI 55.05
- ALZN 43.21
- Support Level
- POAI $0.90
- ALZN $2.30
- Resistance Level
- POAI $1.08
- ALZN $2.42
- Average True Range (ATR)
- POAI 0.07
- ALZN 0.11
- MACD
- POAI 0.00
- ALZN 0.02
- Stochastic Oscillator
- POAI 36.09
- ALZN 40.73
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.